Spinifex raises $48m for pain drug trials
11 April, 2014 by Dylan Bushell-EmblingUQ spinoff Spinifex has raised $47.7m in series C investment funding to help accelerate the clinical development of neuropathic and inflammatory pain drug EMA401.
Osprey's pilot diabetic limb trial a success
10 April, 2014 by Dylan Bushell-EmblingOsprey Medical's (ASX:OSP) Limb Recovery System reduced bacterial load in patients with diabetic foot infections during a pilot trial - so much so that one patient escaped the need for amputation.
CEO focus groups gather leaders' views
10 April, 2014Biotech and medtech leaders are participating this week and next in focus groups to share their views and perspectives on industry policy and bolster the 2014 Biotechnology Industry Position Survey, due for release in May.
Avita Medical improves ReCell Spray-on Skin
09 April, 2014 by Dylan Bushell-EmblingAvita Medical (ASX:AVH) announced the EU launch of a version of its ReCell Spray-on Skin that eliminates the requirement for refrigeration, but the new version is not yet approved in Australia.
'Soft Landing' program to support access to Hong Kong and China
08 April, 2014Hong Kong's 'Soft-landing Programme for Technology and Innovation Collaboration' is open to technology transfer offices (TTOs), research and development centres, research institutes and spin-out companies of overseas universities interested in exploring the Asian market, especially mainland China.
GI Dynamics scores Israeli win for EndoBarrier
08 April, 2014 by Dylan Bushell-EmblingGI Dynamics (ASX:GID) has revealed that its EndoBarrier therapy now has reimbursement coverage at one of Israel's four HMOs, and is now on offer at two more Australian clinics.
Reva fixed in focus on Fantom
07 April, 2014Reva sticks to expediting its biodegradable stent Fantom to the clinic.
Global Kinetics to present at philanthropic forum
07 April, 2014 by Dylan Bushell-EmblingMelbourne's Global Kinetics will present details of the company and its Parkinson's Kinetograph symptom-monitoring device at a global philanthropic forum in New York in May.
A new funding program to support biopharmaceutical manufacturing development
03 April, 2014The first round of a new pilot funding program opens this week in Queensland, with at least $2 million available for biopharmaceutical product developers wanting to make use of BioPharmaceuticals Australia's (BPA) new mammalian cell contract manufacturing facility, operated by DSM Biologics (DSMB).
Simon McKeon to give National Press Club Address
01 April, 2014AusBiotech has welcomed news that Simon McKeon AO will speak at the National Press Club in Canberra about the Strategic Review of Health and Medical Research in Australia.
Analytica close to US, EU filings for PeriCoach
01 April, 2014 by Dylan Bushell-EmblingAnalytica (ASX:ALT) will soon be ready to file EU CE Mark and US 510(k) submissions for PeriCoach, a device for treating female urinary incontinence that is already approved in Australia.
dorsaVi teams with insurer to promote OHS device
01 April, 2014 by Dylan Bushell-EmblingdorasVi (ASX:DVL) has entered a partnership with insurer Allianz to recommend the use of ViSafe - a device for measuring movement and muscle activity - for Australian labourers.
pSivida partner files fourth US NDA for Iluvien
31 March, 2014 by Dylan Bushell-EmblingpSivida (ASX:PVA) licensee Alimera Sciences has made its third resubmission of its US New Drug Application for diabetic macular edema treatment Iluvien.
GI Dynamics hits Netherlands reimbursement milestone
28 March, 2014 by Dylan Bushell-EmblingA Dutch hospital has won approval to be reimbursed for some procedures involving GI Dynamics' (ASX:GID) EndoBarrier so that healthcare authorities can evaluate allowing nationwide reimbursement.
Government releases statement on the Pharmaceutical Patents Review
27 March, 2014The federal government last week released a statement on the Pharmaceutical Patents Review report, confirming it "has no plans to respond to the report at this stage".
